Advate used in the treatment of hemophilia A - Cost-effectiveness analysis of treatment versus on-demand. prophylaxis based product sull'emivita;Advate nel trattamento dell'emofilia A - Analisi costo-efficacia della terapia on-demand vs. profilassi basata sull'emivita del prodotto

Italian Journal of Public Health

Volumn 8, Issue 2 SUPPL. 1, 2011, Pages

  Capri, Stefano ^a   Ricciardi, Walter ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80052715247     PISSN: 17237815     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. NICE. Appraising Orphan Drugs, 16 March 2006.
2. Drummond MF, Wilson DA, Kanavos P et al. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care 2007;23:36-42.
3. O'Mahony B, Noone D, Tolley K. An introduction to key concepts in health economics for hemophilia organizations. Hemophilia Organization Development, July 2010, No 11.
4. Miners A. Revisiting the cost-effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia A. Haemophilia 2009;15:881-887.
5. Miners AH, Sabin CA, Tolleyk H, Lee CA. Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia. Pharmacoeconomics 2002;20: 759-774.
6. Triemstra AHM, Smit C, Van der Ploeg HM, et al. Mortality in patients with hamophilia. Ann Intern Med 1995;123:823-827.
7. Miners A, Sabin CA, Tolley CH et al. Assessing health-related quality of life in individuals with heamophilia. Haemophilia 1999;5:378-385.
8. Capri S, Ceci A, Terranova L, et al. Guidelines for economic evaluations in Italy: Recommendations from the Italian Group of Pharmacoeconomic Studies. Drug Inf J 2001;35:189-201.
9. AIES. Proposta di linee guida per la valutazione economica degli interventi sanitari in Italia. PharmacoEconomics, Italian Research Articles 2009;11(2):83-93.
10. Lippert B, Berger K, Berntorp E et al. And The European Haemophilia Economic Study Group. Cost-effectiveness of haemophilia treatment: a cross-national assessment. Blood Coagul Fibrinolysis 2005;16:477-485.
11. Risenbrough N, Oh P, Blanchette V, et al. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxisand on-demand therapy in young children with severe haemophilia A. Haemophilia 2008;14:743-752.
12. Axelsen F and Miners A. Assessing the cost-effectiveness of primary prophylaxis for the treatment of severe haemophilia A. Poster presented at ISPOR. Prague, Czech Republic 6-9 November 2010.
13. Oldenburg J, Goudemand J, Valentino L, et al. Post-Authorization Safety Surveillance of ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] Demonstrates Efficacy, Safety and Low-Risk for Immunogenicity in Routine Clinical Practice. Haemophilia 2010;16(6):866-877.